Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
An affordable pill could shake up lupus treatment. A Chinese randomized trial found that sirolimus — a powerful immunosuppressant — helped over half of patients with hard-to-treat lupus achieve meaningful clinical improvement, compared to just 23% on placebo. The catch? Lab abnormalities were common, and longer-term safety data is still pending.
An old drug, a new role. A 145-patient, double-blind, placebo-controlled trial out of China found that sirolimus — an oral immunosuppressant already used in transplant medicine — significantly outperformed placebo in patients with systemic lupus erythematosus (SLE) that wasn't controlled by standard therapy. Over 54% of sirolimus-treated patients hit the primary endpoint (SRI-4 response) at 24 weeks, versus just 23% on placebo. All secondary endpoints also favored the drug.
The safety picture is mixed. Serious infections were rare (only 2 out of 70 patients), and just 4 patients stopped the drug due to side effects. However, lab abnormalities were widespread — including elevated triglycerides (50%), high cholesterol (37%), and leukopenia (27%). Longer-term clinical consequences remain unknown, with an open-label extension phase still ongoing.
By the Numbers:
Why it matters: Biologics like belimumab work well for refractory lupus, but cost and access remain real barriers. Sirolimus — a shelf-stable, oral, and more affordable alternative — could offer a meaningful option for patients who can't readily access biologics, both in the U.S. and globally.
